Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection
Microbiology Spectrum · 04.08.2026 · 14 (8)
DOI: 10.1128/spectrum.03996-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.08.2026. Verfasst von Bo Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hematologic Neoplasms, COVID-19, Proteomics. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding (Interdisciplinary Clinical Research Project of Peking University First Hospital), Beijing Natural Science Foundation.
Abstract (Originalsprache)
Patients with hematologic malignancies (HMs) are particularly vulnerable to coronavirus disease 2019 (COVID-19) because of underlying immune dysfunction and treatment-related immunosuppression. However, proteomic features associated with different clinical trajectories in this population remain insufficiently characterized. We performed serum proteomic analysis in 40 HM patients with COVID-19 and 15 healthy controls. Compared with controls, HM patients showed impaired immune-related responses during the acute phase of COVID-19. Acute-phase proteomic patterns differed across outcome groups; however, because outcome groups were closely intertwined with initial COVID-19 severity, ICU admission, and systemic illness, and because multivariable adjustment was not performed due to the limited sample size, these patterns should be interpreted as severity- and outcome-associated profiles rather than independent trajectory-specific markers. Fatal cases showed evidence of dysregulated immune activation, whereas patients later classified as having long COVID exhibited broader suppression of immune-related pathways. In addition to immune alterations, pathways related to platelet activation and cardiac-related dysfunction were associated with adverse clinical trajectories. Enzyme-linked immunosorbent assay validation supported the association of selected proteins with outcome groups during acute infection. These findings provide a proteomic overview of COVID-19 in HM patients and offer a basis for future mechanistic studies and larger external validation cohorts. IMPORTANCE Patients with hematologic malignancies are highly vulnerable to severe coronavirus disease 2019 (COVID-19), acute death, and long COVID due to preexisting immune dysfunction. However, the proteomic signatures linked to adverse clinical trajectories remain poorly understood. Our serum proteomic study identifies distinct acute-phase immune profiles associated with different outcomes: broad immune suppression characterizes long COVID, while dysregulated immune activation is associated with fatal cases. Platelet activation and cardiac-related pathways are also linked to poor outcomes. These findings provide key molecular insights for this high-risk population, supporting future biomarker development, risk stratification, and targeted clinical management. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT05683353 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking University First Hospital, Beijing, China.
- Center for Precision Medicine Multi-Omics Research, Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
- Department of Biochemistry and Biophysics, Center for Precision Medicine Multi-Omics Research, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
ORCID-Profile: Bo Tang, Xiaodi Yang, Yujun Dong
Förderung
- National High Level Hospital Clinical Research Funding (Interdisciplinary Clinical Research Project of Peking University First Hospital)
- Beijing Natural Science Foundation
Zitieren
APA
Tang, B., Yang, X., Tian, W., Zhu, J., Liu, W., Di, M., Liu, H., Liang, Z., Chen, Y., & Dong, Y. (2026). Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection. Microbiology Spectrum, 14(8). https://doi.org/10.1128/spectrum.03996-25
Vancouver
Tang B, Yang X, Tian W, Zhu J, Liu W, Di M, et al. Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection. Microbiology Spectrum. 2026;14(8). doi:10.1128/spectrum.03996-25
BibTeX
@article{Tang2026,
author = {Tang, Bo and Yang, Xiaodi and Tian, Wenmin and Zhu, Jialin and Liu, Wei and Di, Mingyi and Liu, Huihui and Liang, Zeyin and Chen, Yang and Dong, Yujun},
title = {Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection},
journal = {Microbiology Spectrum},
year = {2026},
volume = {14},
number = {8},
doi = {10.1128/spectrum.03996-25}
}
EUVIMED